[{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Noveome Biotherapeutics \/ Parexel","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Parexel"},{"orgOrder":0,"company":"Noveome Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Noveome Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Noveome Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Noveome Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"LaSanta S A S","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"LaSanta S A S","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"LaSanta S A S \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"LaSanta S A S \/ Inapplicable"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"NB1000S","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Novome Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"E2Bio Life Sciences","sponsor":"Hematology Center after Prof. R. Yeolyan","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"E2Bio Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Gargle\/Mouthwash","sponsorNew":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan","highestDevelopmentStatusID":"7","companyTruncated":"E2Bio Life Sciences \/ Hematology Center after Prof. R. Yeolyan"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.23000000000000001,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ AzurRx BioPharma","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ AzurRx BioPharma"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Ziauddin University","sponsor":"Hilton Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Saccharomyces Cerevisiae","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Ziauddin University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ziauddin University \/ Hilton Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Ziauddin University \/ Hilton Pharma"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"ExeGi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"EXE-346","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"ExeGi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExeGi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ExeGi \/ Inapplicable"},{"orgOrder":0,"company":"Instituto de Investigacion Sanitaria La Fe","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Instituto de Investigacion Sanitaria La Fe","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Perilesional Injection","sponsorNew":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"7","companyTruncated":"Instituto de Investigacion Sanitaria La Fe \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2024","type":"Private Placement","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Submucosal Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Bausch Health","highestDevelopmentStatusID":"7","companyTruncated":"Cedars-Sinai \/ Bausch Health"},{"orgOrder":0,"company":"Amy Lightner","sponsor":"Ossium Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Ossium vBM-MSC","moa":"Bone marrow cell","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Amy Lightner","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amy Lightner \/ Ossium Health","highestDevelopmentStatusID":"7","companyTruncated":"Amy Lightner \/ Ossium Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Argon Medical Devices","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Argon Medical Devices","highestDevelopmentStatusID":"7","companyTruncated":"University of Alabama at Birmingham \/ Argon Medical Devices"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"NM-002","moa":"GLP-1 receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"PrecisionBiotics Group Ltd.","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"PrecisionBiotics Group Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PrecisionBiotics Group Ltd. \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"PrecisionBiotics Group Ltd. \/ Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Scioto Biosciences","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series B Financing","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Scioto Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Scioto Biosciences \/ Genome & Company","highestDevelopmentStatusID":"7","companyTruncated":"Scioto Biosciences \/ Genome & Company"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"EP-104IAR","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Eupraxia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Changhai Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Changhai Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Changhai Hospital"},{"orgOrder":0,"company":"Jiangsu Topcel-KH Pharmaceutical","sponsor":"Xiangya Hospital, Central South University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TH-SC01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Topcel-KH Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Topcel-KH Pharmaceutical \/ Xiangya Hospital, Central South University","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Topcel-KH Pharmaceutical \/ Xiangya Hospital, Central South University"},{"orgOrder":0,"company":"Direct Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles","moa":"Progenitor cell","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Direct Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Direct Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Direct Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc."}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : EP-104GI (fluticasone propionate) is a corticosteroid acts on glucocorticoid receptor, currently being investigated for eosinophilic esophagitis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 05, 2025

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Alabama at Birmingham

                          Country arrow
                          ESCRS
                          Not Confirmed

                          University of Alabama at Birmingham

                          Country arrow
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 02, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Argon Medical Devices

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : EP-104GI (fluticasone propionate) is a glucocorticoid receptor agonist which is being evaluated for the treatment for patients with eosinophilic esophagitis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 25, 2025

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : EP-104GI (fluticasone propionate) is a glucocorticoid receptor agonist which is being evaluated for the treatment for patients with eosinophilic esophagitis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : EP-104GI (fluticasone propionate) is a glucocorticoid receptor agonist which is being evaluated for the treatment for patients with eosinophilic esophagitis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          November 09, 2024

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : The company intends to use the net proceeds from the private placement towards the funding of clinical trials for EP104GI (fluticasone propionate) to treat Eosinophilic Esophagitis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          October 31, 2024

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : $44.5 million

                          Deal Type : Private Placement

                          blank

                          07

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Company lead product candidate EP-104GI (fluticasone propionate). which is being evaluated for the safety and efficacy of EP-104GI as a treatment for patients with eosinophilic esophagitis.

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 21, 2024

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 18, 2024

                          Lead Product(s) : ST266

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Parexel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : KAN-101 is an investigational treatment for Celiac Disease (CeD). It encompasses a well-described gluten antigen that is implicated in driving the onset of Celiac Disease.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 05, 2023

                          Lead Product(s) : KAN-101

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : ExeGi investigational product candidate EXE-346, which is a microbiome modulator probiotic. Currently, it is being evaluated in the Phase I/II clinical trial studies for the treatment of excessive stool frequency in patients with an ileal pouch-anal anas...

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          August 12, 2023

                          Lead Product(s) : EXE-346

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank